中国创新药BD出海创历史纪录，恒生创新药ETF（520500）开年以来日均成交额超6亿

Group 1 - The core viewpoint highlights the strong momentum of China's innovative pharmaceuticals in international markets, with a record number of outbound licensing deals and total transaction value in 2025 [2][4] - In 2025, China completed 157 outbound licensing transactions with a total value of $135.655 billion, including $7 billion in upfront payments, marking a historical high [2][4] - China accounted for 49% of the global total of outbound licensing deals in 2025, surpassing the United States for the first time [2][4] Group 2 - The policy environment is supportive, with the Ministry of Commerce and nine other departments issuing guidelines to enhance the drug retail industry and encourage innovative drugs to enter retail channels [2][4] - The continuous growth in business development (BD) transactions in 2025 indicates a sustained high level of industry activity, with expectations for higher transaction values based on early clinical data in 2026 [2][4] - The Hang Seng Innovative Drug ETF (520500) invests in 31 leading Hong Kong innovative pharmaceutical companies, focusing on key areas such as biopharmaceuticals and chemical drugs [3][4] Group 3 - The Hang Seng Innovative Drug ETF (520500) has a significant scale and liquidity, supporting T+0 trading, making it an effective tool for investors to capture opportunities in the Hong Kong innovative drug market [4][9] - The ETF's management by Huatai-PB Fund, a pioneer in ETF management in China, adds credibility and expertise to its operations [10]